1
|
Allahyani M, Alshalawi AM, Alshalawii MR, Alqorashi SA, Aljuaid A, Almehmadi MM, Bokhary MA, Albrgey AS, Alghamdi AA, Aldairi AF, Alhazmi AS. Phenotypical evaluation of lymphocytes and monocytes in patients with type 2 diabetes mellitus in Saudi Arabia. Saudi Med J 2023; 44:296-305. [PMID: 36940958 PMCID: PMC10043885 DOI: 10.15537/smj.2023.44.3.20220873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Accepted: 02/15/2023] [Indexed: 03/22/2023] Open
Abstract
OBJECTIVES To evaluate the levels of total lymphocytes, B-lymphocytes (CD19+), T-lymphocytes (CD3+), natural killer (NK) cells (CD3-/CD56+), and monocyte subsets in type 2 diabetes mellitus (T2DM) patients in Saudi Arabia. In addition, this study aimed to evaluate whether B- and T-lymphocyte subsets are frequently altered in patients with T2DM. METHODS A case-control study included 95 participants recruited in the study: 62 patients with T2DM and 33 healthy individuals. All the patients were admitted to the Diabetic Centre in Taif, Saudi Arabia. Blood samples were collected between April and August 2022. The hemoglobin A1c (HbA1c) level was evaluated in all patients. Flow cytometry was used to measure the expression of B-lymphocyte, T-lymphocyte, NK cells, and monocyte markers. The unpaired t-test was carried out to evaluate the differences in these markers between T2DM patients and healthy individuals. RESULTS Patients with T2DM were associated with a lower percentage of total lymphocytes, higher percentage of B-lymphocytes, naive, and memory B subsets. In addition, patients with T2DM showed lower percentage of total T-lymphocytes (CD3+) and CD4 T-cells, but higher CD8 T-cell expression. Also, the NK-cell level was reduced in patients with T2DM, and the levels of monocyte subsets were altered. CONCLUSION These data suggested that levels of lymphocytes and monocytes are impaired in T2DM patients, and this might be associated with the higher risk of infections observed in these patients.
Collapse
Affiliation(s)
- Mamdouh Allahyani
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Amani M. Alshalawi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Maram R. Alshalawii
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Shahad A. Alqorashi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Abdulelah Aljuaid
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Mazen M. Almehmadi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Mohammed A. Bokhary
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Alhanouf S. Albrgey
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Ahmad A. Alghamdi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Abdullah F. Aldairi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| | - Ayman S. Alhazmi
- From the Department of Clinical Laboratory Sciences (Allahyani, Alshalawi, Alshalawii, Alqorashi, Aljuaid, Almehmadi, Alghamdi, Alhazmi), College of Applied Medical Sciences, Taif University, from the Department of Clinical Chemistry (Bokhar); from the Department of Endocrinology and Diabetic Centre (Albrgey), King Abdulaziz specialist hospital, Ministry of Health, Taif, and from the Department of Laboratory Medicine (Aldairi), Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
| |
Collapse
|
2
|
Li CH, Fan X, Lv SX, Liu XY, Wang JN, Li YM, Li Q. Clinical and Computed Tomography Features Associated with Multidrug-Resistant Pulmonary Tuberculosis: A Retrospective Study in China. Infect Drug Resist 2023; 16:651-659. [PMID: 36743337 PMCID: PMC9897068 DOI: 10.2147/idr.s394071] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Accepted: 01/06/2023] [Indexed: 02/03/2023] Open
Abstract
Purpose To explore the value of integrating clinical and computed tomography (CT) features to predict multidrug-resistant pulmonary tuberculosis (MDR-PTB). Patients and Methods The study included 212 patients with MDR-PTB and 180 patients with drug-sensitive pulmonary tuberculosis (DS-PTB) who referred to our institute in China between January 2016 and March 2021. The clinical and CT characteristics were analyzed and compared between both groups. Multivariable logistic regression analysis was performed to identify independent factors that can be used to predict MDR-PTB. Furthermore, 115 patients admitted to another center from January 2019 to January 2022 were included as external validation cohort. Results For clinical characteristics, five parameters were significantly different between the two groups (all P < 0.05). With regard to CT features, nine parameters were significantly different between the two groups (all P < 0.05). Multivariable logistic regression analysis using the aforementioned differential features showed that male sex, retreated history, longer duration of previous anti-TB treatment, lower CD4+ T lymphocyte count, thick-walled cavity, centrilobular micronodules and tree-in-bud sign, bronchial stenosis, pleural and pericardial thickening were the most effective variations associated with MDR-PTB with an area under the curve (AUC) of 0.849 and accuracy of 78.6%. Furthermore, the external validation cohort that contains 115 patients obtained an AUC of 0.933 and accuracy of 81.7%. Conclusion MDR-PTB and DS-PTB have different clinical and imaging characteristics. A combined model incorporating these differential features can promptly diagnose MDR-PTB and develop subsequent therapeutic strategies.
Collapse
Affiliation(s)
- Chun-Hua Li
- Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China,Department of Radiology, Chongqing Public Health Medical Center, Chongqing, People’s Republic of China
| | - Xiao Fan
- Department of Radiology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, People’s Republic of China
| | - Sheng-Xiu Lv
- Department of Radiology, Chongqing Public Health Medical Center, Chongqing, People’s Republic of China
| | - Xue-Yan Liu
- Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China,Department of Radiology, Chongqing Public Health Medical Center, Chongqing, People’s Republic of China
| | - Jia-Nan Wang
- Department of Radiology, Chongqing Public Health Medical Center, Chongqing, People’s Republic of China
| | - Yong-Mei Li
- Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
| | - Qi Li
- Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China,Correspondence: Qi Li; Yong-Mei Li, Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing, 400016, People’s Republic of China, Tel +0086 15823408652, Fax +0086 23 68811487, Email ;
| |
Collapse
|
4
|
Syukri A, Budu, Hatta M, Amir M, Rohman MS, Mappangara I, Kaelan C, Wahyuni S, Bukhari A, Junita AR, Primaguna MR, Dwiyanti R, Febrianti A. Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1-α and VEGF pathway in progressive of cardiovascular damage. Ann Med Surg (Lond) 2022; 76:103501. [PMID: 35340325 PMCID: PMC8943401 DOI: 10.1016/j.amsu.2022.103501] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 03/08/2022] [Accepted: 03/08/2022] [Indexed: 02/06/2023] Open
Abstract
Background Doxorubicin (DOX) is a commonly used treatment for cancer and the mechanism of DOX-induced cardiomyocyte damage in cardiovascular disease is not fully understood. High-mobility group box 1 (HMGB1), strong induce proinflammatory cytokines via damage associated molecular pattern (DAMP) which its interaction with the receptor of advanced glycation end products (RAGE), that affect cytokine release, and angiogenesis via the role of HMBG1, HIF-1α and VEGF as an important regulator in these cardiac failure processes. Hypoxia-inducible factor-1α (HIF-1α) is plays an important role in the cellular response to systemic oxygen levels of cells and VEGF is an angiogenic factor and can stimulate cellular responses on the surface of endothelial cells will be described Objective The aim of this article is to comprehensively review the role of HMGB1, HIF-1α, and VEGF in DOX-induced Cardiovascular Disease and its molecular mechanisms. Methods The data in this study were collect by search the keyword combinations of medical subject headings (MeSH) of “HMGB1”, “HIF-1 α”, “VEGF”, “DOX” and “Cardiovascular disease” and relevant reference lists were manually searched in PubMed, EMBASE and Scopus database. All relevant articles in data base above were included and narratively discussed in this review article. Results Several articles were revealed that molecular mechanisms of the DOX in cardiomyocyte damage and related to HMGB1, HIF-1α and VEGF and may potential treatment and prevention to cardiovascular disease in DOX intervention. Conclusion HMGB1, HIF-1α and VEGF has a pivotal regulator in DOX-induce cardiomyocyte damage and predominantly acts through different pathways. The role of HMGB1 in DOX-induced myocardial damage suggests that HMGB1 is a mediator of DOX-induced damage. In addition, DOX can inhibit HIF-1α activity where DOX can decrease HIF-1α expression and HIF-1α is also responsible for upregulation of several angiogenic factors, including VEGF. VEGF plays an important role in angiogenesis and anti-angiogenesis both in vitro and in vivo and reduces the side effects of DOX markedly. In addition, the administration of anti-angiogenesis will show an inhibitory effect on angiogenesis mediated by the VEGF signaling pathway and triggered by DOX in cells. The effect of Doxorubicin (DOX) induced cardiovascular damage via several pathways. Cardiovascular damage can involve HMGB1, HIF-1α, and VEGF. HMGB1, HIF-1α, and VEGF as a pivotal regulator in DOX-induce cardiomyocyte damage. HMGB1, HIF-1α, and VEGF in cardiovascular diseases will be predominantly acting through different pathways.
Collapse
|
5
|
Fachri M, Hatta M, Widowati E, Akaputra R, Dwiyanti R, Syukri A, Junita AR, Febrianti A, Primaguna MR. Correlations between comorbidities, chest x-ray findings, and C-Reactive protein level in patients with COVID-19. Ann Med Surg (Lond) 2022; 77:103553. [PMID: 35382457 PMCID: PMC8972967 DOI: 10.1016/j.amsu.2022.103553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/26/2022] [Accepted: 03/26/2022] [Indexed: 01/08/2023] Open
Abstract
Background Patients with comorbidities have an increased risk for severe coronavirus disease (COVID-19) symptoms, including abnormal inflammation. Chest X-rays and C-reactive protein (CRP) level are frequently used to evaluate the severity of inflammation. The aim of this study was to investigate the correlation between comorbidities, chest X-ray findings, and CRP level in patients with COVID-19. Materials and methods This was a cross-sectional, analytic, observational study performed using a quantitative approach. The study population included in patients with confirmed COVID-19. Secondary data from the medical records of the patients were analysed to determine the correlations between comorbidities, chest X-rays, and CRP level. Results The data of 167 patients (87 [52.1%] females and 80 [47.9%] males) were evaluated. Regarding comorbidities, 86 (51.5%) patients had hypertension, 66 (39.5%) had diabetes mellitus, and 17 (10.2%) had dyspepsia. Chest X-rays showed that 144 (86.2%) patients had pneumonia, whereas 23 (13.8%) did not. A total of 143 (85.6%) patients showed increased CRP levels, whereas 24 (14.4%) did not show any increase. Patients who showed pneumonia on chest X-rays tended to have increased CRP levels. The results also showed that chest X-ray findings were correlated with CRP level. Diabetes mellitus and hypertension were significantly correlated with CRP level (p = 0.05), whereas dyspepsia did not show a significant relationship with CRP level (p > 0.05). Patients with hypertension had a 2.709-fold risk of having increased CRP level compared with patients without hypertension. Patients with pneumonia had a 2.953-fold increased risk for increased CRP level compared to those without pneumonia. Conclusion Hypertension and diabetes mellitus are significantly correlated with CRP level. Chest X-ray finding is also significantly correlated with CRP level. The most common comorbidity in COVID-19 patients is hypertension. Most COVID-19 patients with pneumonia tend to increase CRP value. Only hypertension and diabetes mellitus have a significant correlation with the CRP value. The chest x-ray result has a significant correlation with the CRP value.
Collapse
|